Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone Added to Ropivacaine for TAP Block and Perioperative Neurocognitive Disorders in Colorectal Cancer Surgery
ChiCTR2400093608Phase 4Not yet recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in perioperative neurocognitive disorder comparing Control TAP block (ropivacaine alone) with Hydromorphone + ropivacaine TAP block (2 arms). Primary endpoint: Incidence of perioperative neurocognitive disorders (PND). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
hydromorphoneropivacaine
03
Conditions
perioperative neurocognitive disorder
Beyond the preview
Go deeper on ChiCTR2400093608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093608.